Promising Respiratory Drug Focus of New Clinical Trial for Parkinson's Disease
A medication that has been approved to treat various respiratory diseases is now serving as the focal point of a new clinical trial for Parkinson’s disease. This trial is launched as part of the Linked Clinical Trials (LCT) intiative, in collaboration with The Cure Parkinson’s Trust and the Van Andel Research Institute (VARI). “With this trial, we’re moving beyond treating Parkinson’s symptoms. We want to actually slow or stop disease progression,” said Patrik Brundin, MD, PhD, head of LCT’s international scientific committee and director of VARI’s Center for Neurodegenerative Science. “This drug – ambroxol – has performed exceptionally well in preclinical studies for Parkinson’s and is already approved to treat other conditions.” To read more, click here.
2017 AANS/CNS Section on Pediatric Neurological Surgery
Nov. 28-Dec. 1, 2017; Houston
2nd Homburg ICP and Hydrocephalus Workshop
Nov. 28-30, 2017; Germany
22nd Instructional Course and 45th Annual Meeting of the Cervical Spine Research Society
Nov. 29, 2017 - Dec. 2, 2017; Hollywood, Fla.